Community feedback highlights the importance of CF care teams, in-person CF care, and telehealth.
Long-standing volunteers Kate O’Donnell and Amy Barry to co-chair major gift and planned giving campaign, continuing the legacy of beloved philanthropic leader Joe O’Donnell
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Revised approach to lung function reporting is shown to be more scientifically accurate and may reduce health disparities.
This year’s program marked the largest in-person advocacy event in the Foundation’s history.
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
A transformative leader for more than two decades, Marshall will transition to advisory role
Prime Medicine’s prime editing technology has the potential to bring genetic therapies to all people with cystic fibrosis, ultimately paving the way to a cure.
The Foundation is committed to improving health outcomes for people with cystic fibrosis from underrepresented groups by supporting research projects advancing our understanding of barriers to health equity.